Reasons for Malaria’s Drug Resistance
News Dec 15, 2014
Malaria is a mosquito-borne parasite which affects over 60 million people worldwide and in serious cases, can be fatal. There is currently no viable vaccine for malaria while antimalarial drugs and prophylaxis are losing its efficacy with increasing drug resistance.
NTU Associate Professor Zbynek Bozdech, who led an international research team from 11 different countries, said knowing how the malaria parasite is developing drug resistance will help healthcare workers better treat patients suffering from malaria infections.
Using a cost-effective microarray technique, Prof Bozdech’s team from NTU’s School of Biological Sciences, analysed 1,000 malaria samples taken from patients in the area of the Greater Mekong Subregion.
The Greater Mekong Subregion includes countries such as Cambodia, Thailand, Vietnam, Laos and Myanmar, where various strains of malaria are still prevalent.
Prof Bozdech said the surprising find was that almost all the malaria parasites found in Cambodia and nearby regions had mutated and developed resistance to Artemisinin, the main drug used in combination therapies to treat malaria.
This is a stark difference when compared to malaria parasites from the Congo and other African countries. There, only one to three per cent of the malaria parasites had mutated and drug resistance has not yet been detected in the rest.
“Doctors in the Greater Mekong Subregion are finding that Artemisinin-based treatment – the wonder drug cocktail that can treat patients in three days – is now taking twice as long to work, and in some rare cases, has little to no effect,” said Prof Bozdech, a biochemist and molecular biologist.
“To find out exactly what the parasite cell is doing to protect itself against Artemisinin, we correlated the clinical data of the 1,000 samples with functional genomics results using our own customised techniques.”
NTU research fellow Dr Sachel Mok, the first author of the scientific paper, said they found the malaria parasite's two major ways by which it becomes resistant to Artemisinin.
“First, the malaria parasite increased its capacity to repair the damage caused by the anti-malarial drug which gives it a higher chance of survival,” said the Singaporean researcher.
“Second, because the drug is more effective against the parasite at its later stage of its development, the parasite slowed down its growth so it could survive longer in the younger stages.
“Using methods like gene expression analysis, we linked these two phenomena to a gene named K13, which was previously suggested to be associated with drug resistance but it was not clear how.”
With this new knowledge, doctors will be able to design new strategies for drug treatments, particularly when deciding which cocktail of drugs will work better with Artemisinin to better treat patients.
The findings of this study will also give scientists and governments valuable data on how to better monitor the drug resistance of the malaria parasite and develop more effective ways of combating it.
Prof Bozdech, the Associate Chair for Research at NTU’s School of Biological Sciences, said that overall research has shown that the drug resistance in malaria has been growing in the Greater Mekong Subregion and is likely to spread to surrounding areas.
In addition, other researchers have shown possible cases of monkey malaria spreading to humans in nearby Asian countries. While it is not the first time malaria developed a resistance to previous drugs, Artemisinin is the last effective drug available as new drugs have yet to be developed.
“What history has shown us with the previous drugs is that even with an effective antimalarial drug, all it takes is for something to change in the malaria parasites and we will face a huge challenge trying to contain its growth again,” Prof Bozdech explained.
This four-year research project started by the NTU team was funded by the National Medical Research Council in Singapore.
Their scientific paper involved 31 scientists from 11 countries such as. Thailand, Vietnam, Cambodia, Myanmar, and Laos; with notable partners such as Oxford University in the UK; the University of Maryland, School of Medicine, from United States; as well assistance from the World Health Organisation (WHO).
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Allergy Amplifier Implicated in Asthma Also Intensifies Food AllergyNews
Scientist who previously reported that a small protein, aptly named histamine-releasing factor, played a pro-inflammatory role in asthma have now shown that it also serves as a “food allergy amplifier”. This work paves the way for blood tests to predict which patients will respond to allergy therapy, and strongly supports the idea that drugs designed to block HRF could prevent food allergy attacks.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE